Results 191 to 200 of about 160,871 (266)

Disease‐Duration–Specific Percentiles for Prospective Subtyping of Parkinson's Disease: A PPMI‐Based Study

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Parkinson's disease (PD) is clinically heterogeneous, with variable progression rates that complicate clinical trial design. The data‐driven diffuse malignant (DM), intermediate (IM), and mild‐motor predominant (MMP) subtyping model has prognostic value but lacks disease duration–specific thresholds for prospective use in disease ...
Ahmed Negida, Nitai Mukhopadhyay, Brian D. Berman, Seyed‐Mohammad Fereshtehnejad, Matthew J. Barrett   +4 more
wiley   +1 more source

A53T α-Synuclein Expression is Associated with Altered Dopaminergic-Like Differentiation and Reduced DNA Topoisomerase IIβ Levels in an In Vitro Model of Parkinson's Disease. [PDF]

Mol Neurobiol
Selim A, Avşar T, Neğiş Y, Işık S.
europepmc   +1 more source

Re‐Emergent Postural Tremor Without Clinical Resting Tremor in Parkinson's Disease—A Case Report

Movement Disorders Clinical Practice, EarlyView.
Kevin R.E. van den Berg, Rick C. Helmich
wiley   +1 more source

Acute and Chronic Local Field Potential Recordings in Dystonia—A Systematic Review

Movement Disorders Clinical Practice, EarlyView.
Abstract Dystonia is a hyperkinetic movement disorder increasingly conceptualized as a disorder of distributed network dysfunction involving the basal ganglia, cortex and cerebellum. Local field potentials (LFPs) recorded from deep brain stimulation (DBS) electrodes provide a unique opportunity to characterize the electrophysiological signatures ...
Jack Horan, Eoghan Donlon, Aoibheann Gill, Rosalyn Moran, Conor Fearon, Richard A. Walsh, Catherine Moran   +6 more
wiley   +1 more source

Dysregulation of the Extracellular Matrix in the Synaptic Pathology of Parkinson's Disease: Molecular Mechanisms and Novel Therapeutic Approaches. [PDF]

Life (Basel)
Rubio C, Pérez-Rubio R, Pérez-Villavicencio J, Serrano-García N, Lee Á, Granados-Rojas L, Tena-Suck M, Rubio-Osornio M.   +7 more
europepmc   +1 more source

Machine Learning Prediction of Hoehn and Yahr Scores at 5‐Years Post‐123I‐Ioflupane SPECT Imaging in a Real‐World Parkinson's Disease Dataset

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Parkinson's disease (PD) progression is highly heterogeneous, complicating clinical management and prognostication. While machine learning models have been developed using research datasets such as Parkinson's Precision Medicine Initiative (PPMI) and Parkinson's Disease Biomarkers Program (PDBP), their clinical translatability is ...
Xuehua Ye, Mette Niemann Johansen, Balazs Laczi, Mads Peter Horndrup, Michael Zaucha Sørensen, Rasmus Vestergård Madsen, Jan Wolber, Markus Lonsdale, Annemette Lokkegaard, Renee Miller   +9 more
wiley   +1 more source

Multisystem regulation of reward and addiction: beyond the dopaminergic system. [PDF]

Front Pharmacol
Arias-Carrión O, Ortega-Robles E, Treviño M, Guerra-Crespo M, Manjarrez E, Pöppel E.   +5 more
europepmc   +1 more source

Effect of COMT and UGT1A Variants on Clinical Response to Opicapone in Parkinson's Disease

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Parkinson's disease (PD) is the second most common neurodegenerative disease. Symptomatic treatment is based on dopaminergic replacement. With disease progression, the initial benefit of levodopa becomes inconsistent, and motor complications emerge.
Elena Ojeda‐Lepe, Sergio García‐Díaz, Laura Muñoz‐Delgado, Miguel Martín‐Bórnez, Silvia Jesús, Dolores Buiza‐Rueda, Marta Bonilla‐Toribio, Rafael Díaz‐Belloso, Daniel Macías‐García, Astrid Adarmes‐Gómez, Antonio Luque‐Ambrosiani, Rocío Pineda‐Sánchez, Lorena Clavijo‐Jiménez, Fátima Carrillo‐García, Pilar Gómez‐Garre, Pablo Mir   +15 more
wiley   +1 more source

Restless Legs Syndrome and Neurological Comorbidities: A Narrative Review. [PDF]

J Clin Med
Ghattas K, Hernandez H, Huh Y, Fast Z, Wei Z.   +4 more
europepmc   +1 more source